Crown Bioscience Inc.
Novel Preclinical Research Tools Provide Humanized Immune Response to Advance Immunotherapeutic Development, Live Webinar Hosted by Crown Bioscience
SANTA CLARA, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces a live webinar to be presented by Dr. Michelle Mack, Director of Global Scientific Engagement, entitled "Beyond Syngeneics - Novel Tools for Addressing Human Specificity in Immuno-Oncology."
Checkpoint inhibitors like anti-PD-1, anti-PD-L1, and anti-CTLA-4 have revolutionized cancer treatment and have recently gained approval in several cancer types. Despite their potential, immunotherapies face significant development challenges due to the specificity and complexity of the human immune system upon which they act. Crown Bioscience has generated innovative research models to address these obstacles early during preclinical drug development.
This webinar will introduce novel tools for investigating human immune response in immunocompetent systems. This platform includes models that express humanized immune checkpoint inhibitors and ligands created via CRISPR/Cas9 gene editing. The validation of the platform will be detailed to demonstrate its reliability and utility to inform immuno-oncology efficacy studies.
"Crown Biosciences recognizes the importance of providing innovative tools for the evaluation of new therapies, especially in complex applications like immuno-oncology," said Laurie Heilmann, Chief Business Officer at Crown Bioscience. "By attending this webinar, researchers will learn how to use our unique platform to transform their preclinical immunotherapeutic programs."
Join Dr. Mack on Tuesday, October 31 at 10:00 am EDT for an informative session. For details or to register for this complimentary event, visit: Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
About Dr. Michelle Mack
Michelle Mack, Director of Scientific Engagement at Crown Bioscience brings 15 years of previous Oncology R & D experience from Pfizer Inc., where she was a Senior Scientist in the Oncology Research Unit and served as a research project leader on oncology therapeutic programs. At Pfizer, she led cross-functional teams exploring approaches that included: small-molecule inhibitors, antibody drug conjugates and nanoparticle based therapeutics. Michelle's scientific expertise spans the preclinical and translational space for multiple solid and hematological tumor indications. Throughout her professional career, Michelle has worked in Oncology, Immunology and Immuno-Oncology therapeutic areas. She has several high-impact peer-reviewed publications and has led discussions at multiple scientific conferences.
Crown Bioscience Inc. firstname.lastname@example.org
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Venanpri Group23.3.2018 12:01 | pressemeddelelse
Agrisolutions Acquires Trinity
Crown Bioscience Inc.22.3.2018 14:45 | pressemeddelelse
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
SEMAFO Inc.22.3.2018 12:01 | pressemeddelelse
SEMAFO: Construction of Boungou Mine 87% Complete
3Gtms21.3.2018 15:02 | pressemeddelelse
3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems
Addivant21.3.2018 14:39 | pressemeddelelse
Addivant Announces Price Increases on Hindered Amine Light Stablizers
VistaJet Ltd21.3.2018 14:19 | pressemeddelelse
VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum